On your recommendation I looked at CNAT. Looks like that drug has been tested on a wide variety of diseases. I have no idea why GALT isn't pursuing a similar pathway. I also saw the level of dosing and the frequency. They are meeting their endpoints and looks to be an approvable drug but this GRMD-02 is given so infrequently and in such a low dosage compared to CNAT they could learn a thing or two. I don't know why these two companies don't merge and do something huge. Im not entirely sure of the safety profile given their presentation format, but based on the mechanism of action I don't think there are going to be any SAE's.
News 
Market Data 
Discover 
